J&J cancer drug patent invalidated by U.S. court, hitting UK's BTG
Johnson & Johnson's patent on its prostate cancer drug Zytiga was invalidated by a U.S. judge, bringing rivals closer to selling generic versions.
Thursday, January 18, 2018
J&J cancer drug patent invalidated by U.S. court, hitting UK's BTG
J&J cancer drug patent invalidated by U.S. court, hitting UK's BTG
Johnson & Johnson's patent on its prostate cancer drug Zytiga was invalidated by a U.S. judge, bringing rivals closer to selling generic versions.
Related Posts:
0 comments:
Post a Comment